Contact Us
  |  
  Search
Friday, 26 May 2017
Subscribe to newsletter
Ambassadors Program

LSQ will continuously engage with global thought-leaders across all life sciences areas and throughout each year will identify a number of these active, high calibre, well regarded and highly visible individuals and appoint them as LSQ Ambassadors.

The appointment of an LSQ Ambassador will be seen as highly prestigious, and will signify to all that these are indeed global citizens whose efforts impact widely. Each of these honorary appointments will be for an initial period of three years and may be extended by mutual agreement.

These Ambassadors will become defacto international representatives of the Queensland life sciences industry and may be called upon to represent LSQ at particular international forums.

As a group, the LSQ Ambassadors will be seen as an international advisory committee to further steer and nurture the growth of the Queensland life sciences industry.

Most Recent Ambassadors

 

Dr Jaleh Daie - Managing Partner, Aurora Equity

Hall of Famer of Women in Technology and recipient of US Congressional Citation, Dr. Jaleh Daie is a versatile and strategic leader with a record of impactful contributions in private and public sectors. She has held leadership positions in business, academia and government. She has had the honor of serving the administrations of three Presidents and has been featured in major media (ABC, CBS, PBS, NY Times, SV Business Journal, SF Chronicle). A noted life scientist and expert in agriculture and food, Jaleh has extensive board and executive experience. She has global point of view and cultural acumen shown by her extensive international engagements through work in eight countries and numerous global speeches including the Biotech Distinguished Speaker Series in South Africa.

Jaleh is currently managing partner at Aurora Equity and founding chair of AgFoodTech at the Band of Angels in Silicon Valley. Previously, she was head of science at Packard Foundation and managed a $120 million annual budget. Jaleh started her career at Rutgers University and UW-Madison. Jaleh has served on numerous boards in the private and public arena. She has been recognized with Teksia Lifetime Achievement Award; honorary doctoral degree, Fellow of AAAS and AWIS and Scientist’s “Leaders of Science”. 


 

Prof Josh Lerner - Professor of Investment Banking at Harvard Business School

Josh Lerner is the Jacob H. Schiff Professor of Investment Banking at Harvard Business School, and head of the Entrepreneurial Management unit. He graduated from Yale College with a special divisional major that combined physics with the history of technology. He worked for several years on issues concerning technological innovation and public policy at the Brookings Institution, for a public-private task force in Chicago, and on Capitol Hill. He then earned a Ph.D. from Harvard’s Economics Department.

Much of his research focuses on venture capital and private equity organizations. (This research is collected in three books, The Venture Capital Cycle, The Money of Invention, and Boulevard of Broken Dreams.) He also examines policies on innovation and how they impact firm strategies. (That research is discussed in the books Innovation and Its Discontents, The Comingled Code, and the Architecture of Innovation.) He co-directs the National Bureau of Economic Research’s Productivity, Innovation, and Entrepreneurship Program and serves as co-editor of their publication, Innovation Policy and the Economy. He founded and runs the Private Capital Research Institute, a nonprofit devoted to encouraging access to data and research about venture capital and private equity, and serves as vice-chair of the World Economic Forum’s Global Agenda Council on the Future of Investing.

In the 1993-1994 academic year, he introduced an elective course for second-year MBAs. Over the past two decades, "Venture Capital and Private Equity" has consistently been one of the largest elective courses at Harvard Business School. (The course materials are collected in Venture Capital and Private Equity: A Casebook, now in its fifth edition, and the textbook Venture Capital, Private Equity, and the Financing of Entrepreneurship.) He also teaches a doctoral course on entrepreneurship and chairs the Owners-Presidents-Managers Program and executive courses on private equity.

Among other recognitions, he is the winner of the Swedish government’s Global Entrepreneurship Research Award. He has recently been named one of the 100 most influential people in private equity over the past decade by Private Equity International magazine and one of the ten most influential academics in the institutional investing world by Asset International’s Chief Investment Officer magazine. He currently serves as Vice Chair of the World Economic Forum’s Global Agenda Council on the Future of Investing.

  

 

 Mr Anand Gautam - Director, Biopharmaceutical Innovation Sourcing

With over 15 years of leadership in R&D in Inflammation/autoimmune diseases/Cancer/diabetes and developing innovation strategies in international biotech/pharmaceutical companies, together with over 12 years of academic research in Immunology in prestigious research centres in the US, UK, and Australia, Anand continues to get excited about novel science and its potential for translation into medicine. His overall goal is to help convert 'meaningful scientific discoveries' into real innovation (new medicine) to change people's lives world-wide. The last six years at Novo Nordisk, together with experience in developing biotech companies in Denmark and Australia, have further provided him with a platform to fulfil this ambition.

Anand has a comprehensive list of specialities, he is an immunologist with over 25 years of experience in academia and industry in UK, US, Australia and Denmark (~40 peer reviewed scientific articles/reviews in Immunology - e.g. sobme in Nature, PNAS, J. Exp Med, J. Immunol) .R&D and Business Development / Innovation sourcing world-wide .Direct experience in drug development including IND and transitioning Phase II clinical programs to Phase III in discussions with regulatory authorities (e.g. FDA) .Management of Discovery Research in Industry to early stage clinical development .Innovation strategies and R&D partnerships in Asia with academia and the pharmaceutical industry- particularly in Japan, China and India

 

 To view a list of LSQ's other Ambassadors click here.